Novartis: Malaysia signed MoU only with us

Updated on 5 September 2012

Contributions are made through investments in medical devices, diagnostics and drug delivery systems, looking for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.

There are several countries in Asia Pacific that are looking to promote start-up companies. What made Novartis choose Malaysia for this program?

In Asia, Novartis Venture Funds support companies in Singapore and South Korea. NVF is one of the proposed areas of sustainable cooperation outlined in the MoU between Novartis and the MoH. By evaluating promising Malaysian healthcare start-up companies for potential investment, Novartis aims to contribute to the development of the healthcare industry in Malaysia in line with the MoHs's vision and strategy.

What are the future plans of the Novartis corporation in Malaysia?

Novartis remains committed to investing and growing in Malaysia. According to the MoU, Novartis will explore and identify appropriate projects and programs in cooperation with the MoH, which contribute to the country’s economic and social transformation for the benefit of Malaysian patients.

1 2 3 5 Next

Leave a Reply

Post Comment

Special Features

Survey Box

Women in Bioscience

Do you think women and men are equal achievers in the bioscience industry?

Send this article by email

X